Clinical Team

Dr. Siu and Dr. Bedard discuss some data
Dr. Lillian Siu, CGP Executive Director, and Dr. Phillipe Bedard, CGP Clinical Director, discussing patient data

The Cancer Genomics Program, under the direction of Dr. Lillian Siu, Dr. Philippe Bedard and Dr. Suzanne Kamel-Reid, works with medical oncologists at Princess Margaret Cancer Centre to provide molecular profiling services for their patients free of charge. The team consists of oncologists, research scientists, research coordinators, research assistants, and lab technicians dedicated in advancing research in cancer genomics. In 2012, CGP opened its first comprehensive molecular profiling study, IMPACT (Integrated Molecular Profiling in Advanced Cancers Trial)(opens information in a pop-up overlay)

The Role of Oncologists

Medical oncologists and their fellows identify suitable patients for profiling and approach them directly in their clinics. Once the testing is complete, the profiling results are returned to the oncologists directly, and are made available in the patient’s University Health Network medical records.

The oncologists may utilize the results to guide treatment by identifying patients that may benefit from a targeted treatment. Oncologists involved in the molecular profiling initiative meet regularly at a Genomics Tumor Board to discuss any complex cases, and review new topics related to cancer genomics.

Bringing in the Community

In November 2012, the CGP molecular profiling initiative was expanded to community hospitals in Ontario through the parallel arm of the IMPACT study, called COMPACT (Community Oncology Molecular Profiling in Advanced Cancers Trial)(opens information in a pop-up overlay)

Community oncologists are given the opportunity to refer their patients to Princess Margaret for a one-time visit to be offered molecular profiling on their tumor sample. The COMPACT clinic is staffed by three rotating medical oncologists at Princess Margaret: Dr. Lillian Siu, Dr. Philippe Bedard and Dr. Albiruni Razak. Results are returned to the medical oncologist at Princess Margaret who deliver them to the patients directly, and to their respective community oncologists.

Moving Forward

Since opening IMPACT, CGP has opened up many more molecular profiling studies. The CGP team meets regularly to discuss the status of current studies, to develop and validate innovative molecular profiling techniques, and to address scientifically relevant questions in cancer genomics. CGP works closely with the clinical Advanced Molecular Diagnostics Laboratory and the research-oriented Pugh Lab to be able to provide the latest technology in molecular profiling services to cancer patients.

Pointing towards an analysis of patient data